Published in Health Business Week, January 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Decision Resources.
Report 1: Decision Resources has found that the launch of novel, premium-priced drugs and the progression of Wyeth's Mylotarg (gemtuzumab ozogamicin) to a first-line therapy will more than double the market to treat acute myeloid leukemia (AML) by 2015.
The new Pharmacor report "Acute Myeloid Leukemia" finds increased use of Mylotarg and the launches of Genzyme/Bioenvision's Clolar/Evoltra (clofarabine), Vion's Cloretazine (VNP-40101M), and SuperGen/MGI Pharma's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.